Loading…
Loading…
USAQ does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for USAQ and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for USAQ and 80,000+ other tickers.
See exactly how USAQ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for USAQ and 80,000+ other tickers.
QHSLab, Inc. is a company operating in the medical technology and Software-as-a-Service (SaaS) sectors. Its core focus is on advancing value-based healthcare, medical informatics, and personalized medicine driven by algorithms. The firm also develops digital therapeutic solutions and on-site technologies intended for remote patient oversight, the management of chronic conditions, and proactive health maintenance. Among its offerings is a proprietary cloud-based SaaS platform, also known as QHSLab (Quality Health Score Lab expert system). This system empowers physicians and healthcare…
Integrated Service Program (ISP) Revenue More Than Doubles Year-over-Year as Gross Margins Expand and Financing Costs Decline
Unaudited Q1 2026 ISP revenue of $370,000, up from $163,000 in Q1 2025, representing 127% year-over-year growth Growth supported by expanding provider adoption, the launch of the Q-Connect AOM and GLP-1 Support Assessment, and continued development of personalized cardiometabolic health journeys Platform expansion into metabolic and behavioral health strengthens patient engagement and broadens recurring care opportunities West Palm Beach, FL, April 21, 2026 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a digital health company focused on scalable, reimbursable care pathways for primary care and specialty practices, today provided an early second quarter 2026 update to shareholders, highlighting continued growth in its Integrated Service Program (ISP) and the launch of its Q-Connect anti-obesity medications (AOMs) and GLP-1 Support Assessment and Personalized Health Journeys Program. For the first quarter of 2026, the Company generated unaudited ISP revenue of approximately $370,000, compared to $163,000 for the same period in 2025, representing an increase of $207,000, or 127% year-over-year growth.
Integrated Service Program Growth Drives Revenue Expansion and Margin Improvement Delivering Improved Profitability and Debt Reduction in Fiscal 2025 Operational Momentum and Balance Sheet Restructuring Position Company for 2026 Growth West Palm Beach, FL, March 31, 2026 (GLOBE NEWSWIRE) -- QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a digital health infrastructure company focused on enabling independent primary care practices to implement scalable population health screening and care management programs, reported financial results for the year ended December 31, 2025. The Company's platform helps physicians identify and manage underdiagnosed behavioral health and chronic conditions through workflow-integrated digital assessments and follow-up care activities that occur both inside and outside the traditional office visit.
QHSLab, Inc. (OTCMKTS:USAQ - Get Free Report) rose 15.3% on Tuesday. The stock traded as high as $0.7524 and last traded at $0.7242. Approximately 2,346 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 4,315 shares. The stock had previously closed at $0.6279. QHSLab Trading Up 15.3%
STERIS (NYSE: STE - Get Free Report) and QHSLab (OTCMKTS:USAQ - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings. Valuation and Earnings This table compares STERIS and QHSLab"s gross